Previous Article | Next Article ![]()
Molecular and Cellular Biology, January 2003, p. 629-635, Vol. 23, No. 2
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.2.629-635.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710
Received 6 September 2002/ Returned for modification 22 October 2002/ Accepted 25 October 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The RP genes are subject to stringent regulation in order to couple protein synthesis and growth to the availability of nutrients and the physiological status of the cell (48). In addition to the Tor pathway, two other important signaling pathways regulate RP gene expression. The nutrient-sensing protein kinase A (PKA) pathway is required to activate RP gene expression while the PKC pathway mediates repression of RP genes in response to perturbations of the cell integrity pathway (18, 31). Additional signaling programs are also thought to regulate RP gene expression in response to nutrients (30). The majority of RP gene promoters contain binding sites for two transcription factors of partially overlapping function: Abf1 and Rap1 (21, 23; reviewed in reference 33). The most prominent of these factors, Rap1, activates RP gene expression and also functions in silencing telomeres and the silent mating type loci HML and HMR (15, 47).
Gene activation in eukaryotic cells requires mechanisms that overcome the repressive effects of chromatin at specific promoters. A growing body of evidence suggests that this is accomplished by the recruitment of chromatin-remodeling complexes by site-specific transactivators (46). Recent work has demonstrated a strong correlation between recruitment of the Esa1 histone acetylase and transcription from RP gene promoters (37). Furthermore, recruitment of Esa1 to RP gene promoters requires a binding site for Rap1 and/or Abf1 (37). Esa1 is the catalytic subunit of the NuA4 histone acetylase complex that acetylates histones H4 and H2A (1). The NuA4 complex is recruited to DNA by acidic activators such as VP16 and Gcn4 (5).
In this work we examined whether Tor signaling is required for the occupancy of known regulatory factors at the RP gene promoters by using chromatin immunoprecipitation assays. We found that Tor signaling is required for the maintenance of Esa1 at RP gene promoters. Repression of RP genes in response to nutrient depletion or rapamycin treatment requires components of the Rpd3-Sin3 histone deacetylase complex. Our results establish a link between Tor-mediated nutritional signaling and histone acetylation and illustrate a novel mechanistic paradigm by which the Tor pathway controls gene expression.
| MATERIALS AND METHODS |
|---|
|
|
|---|
1278b MATaura3-52 (37). Strains JRY16a, JRY17a, and JRY18a were derived from MLY41a by replacing the entire open reading frame of RPD3, SIN3, and SAP30, respectively, with kanMX. Gene disruptions were all verified by PCR. Chromatin immunoprecipitation and quantitative PCR. Exponentially growing cultures of strain MCY47 containing HA3 epitope-tagged Esa1 were treated with 100 nM rapamycin for 0, 15, 30, and 60 min. Cultures were adjusted to 1% formaldehyde and incubated for 20 min at room temperature with gentle shaking. Glycine was added to a final concentration of 150 mM, and incubation continued for 5 min. Cells were harvested in prechilled bottles and washed twice with ice-cold phosphate-buffered saline. Chromatin was prepared essentially as described previously with the following modifications, and the entire procedure was performed at 4°C (14, 20). Cells were resuspended in 0.8 ml of lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 25 mM ß-glycerophosphate, 25 mM NaF, and protease inhibitors [1 mM phenylmethylsulfonyl fluoride, 1 µg of pepstatin ml-1, 1 mM benzamidine, 1% aprotinin]), an equal volume of 0.5-mm-diameter glass beads was added, and cells were disrupted by vigorous shaking. Glass beads were discarded as indicated (14), and cell lysates were centrifuged at 200,000 x g for 20 min to recover the cross-linked chromatin. The chromatin was resuspended in 0.8 ml of lysis buffer, sonicated to produce fragments with an average size of 350 bp (6 times for 10 s at setting 3 in a Bradson sonicator fitted with a microtip), and centrifuged at 10,000 x g for 15 min. The protein concentrations from the different samples were determined, and 1.8 mg was incubated with antibodies for 2 h. The antibodies used were anti-HA monoclonal antibody F-7, anti-Rap1 (yC-19), anti-Abf1 (yC-20), anti Rpd3 (yN-19 and yC-19) from Santa Cruz Biotechnology and anti-K5, -K8, -K12, and -K16-acetylated histone H4, chromatin immunoprecipitation grade, from Upstate Biotechnology. Immunocomplexes were recovered by adding 30 µl (bead volume) of protein A-Sepharose or protein G-Sepharose. Following incubation for 1 h on a rotator, beads were washed twice with lysis buffer, twice with lysis buffer containing 0.5 M NaCl, twice with 10 mM Tris-HCl (pH 8.0)-0.25 M LiCl-1 mM EDTA-0.5% NP-40-0.5% sodium deoxycholate, and once with Tris-EDTA (TE). All washes were done with a volume of 1.5 ml and for a period of 5 min on a rotator. Immunocomplexes were eluted by incubating the beads in 100 µl of TE-1% sodium dodecyl sulfate at 65°C for 10 min. To reverse the cross-links, the samples were incubated at 65°C overnight and protein was removed by digestion with 100 µg of proteinase K for 2 h at 37°C. Following extraction with phenol-chloroform-isoamyl alcohol, 5 µg of glycogen and 1/10 volume of 5 M LiCl-50 mM Tris-HCl (pH 8.0) were added and DNA was ethanol precipitated overnight at -20°C.
Quantitative PCR in the linear range for each set of primers and DNA was performed as indicated previously (20) with the following modifications. The amount of DNA used for the PCRs for the immunoprecipitates was 1/50 to 1/1,000 of the total sample, and that for the inputs was 1/5,000 to 1/10,000 of the total sample. PCRs were carried out with 15 µl containing 1 µM primers, 125 µM deoxynucleoside triphosphates, 0.1 µCi of [32P]dCTP ml-1 (specific activity, 3,000 Ci mmol-1), 0.37 U of Ex-Taq polymerase, and 5 µl of DNA template. PCR amplification was for 28 to 30 cycles consisting of 30 s at 94°C, 30 s at 55°C, 30 s at 72°C, and finally 5 min at 72°C. For amplification of longer PCR products (see Fig. 4C), PCR amplification was for 35 cycles consisting of 30 s at 94°C, 30 s at 55°C, 2 min at 72°C, and finally 5 min at 72°C. PCR products (typically, 275 to 300 bp) were quantified with a Storm 860 PhosphorImager (Molecular Dynamics), and promoter occupancy was calculated by dividing the amount of PCR product obtained with immunoprecipitated DNA by the amount obtained with total DNA (input).
|
Northern and Western blotting. RNA isolation and Northern blot analysis were performed as described previously (6). Protein extracts were quantitated, and 100 µg of protein was analyzed by Western blotting with the antibodies indicated above for chromatin immunoprecipitation and standard techniques.
| RESULTS |
|---|
|
|
|---|
We examined promoter occupancy by Esa1 in untreated or rapamycin-treated cells by chromatin immunoprecipitation. Rapamycin treatment resulted in a marked release of Esa1 from the promoters of two RP genes, RPL9A and RPS11B, whose expression is known to be inhibited by rapamycin treatment (Fig. 1A and B). In addition, the kinetics of Esa1 release are similar to the kinetics of RP mRNA disappearance. Following 60 min of treatment, Esa1 promoter occupancy was reduced to the background level of detection (see control lanes [beads]) and RP gene mRNAs were nearly undetectable (compare Fig. 1A and B). In agreement with earlier results (37), recruitment of Esa1 to RP gene promoters was specific and only a background level of Esa1 promoter occupancy was observed at the ACT1 promoter, which is not an Esa1 target (Fig. 1A) (37). In accordance with these results, the amount of acetylated histone H4, the major Esa1 substrate (8, 44) diminished at the RP gene promoters while it remained unchanged at the ACT1 promoter (Fig. 1A). These results demonstrate that Tor controls the occupancy of Esa1 at RP gene promoters.
|
An involvement of the Tor pathway in regulating protein stability has been previously reported. Rapamycin treatment leads to a rapid destabilization of the tryptophan amino acid permease Tat2 and the translation initiation factor eIF4G (3, 42). However, the steady-state levels of the Esa1, Rap1, and Abf1 proteins were not affected during the time course of rapamycin treatment in our studies (Fig. 1C). Thus, loss of Esa1 and acetylated histone H4 from RP gene promoters is not attributable to decreases in protein levels.
The Rpd3-Sin3 complex mediates RP gene repression in the absence of Tor signaling. Deacetylation of chromatin by histone deacetylase complexes has been implicated in the repression of genes (reviewed in references 11, 12, and 28). The link between Tor signaling and Esa1-dependent acetylation prompted us to investigate the role of histone deacetylase complexes in RP gene repression. We examined the rapamycin sensitivity of an isogenic set of yeast strains lacking the Hda1, Hos1, Hos2, Hos3, Sir2, or Rpd3 histone deacetylases. Mutations in the Rpd3-Sin3 histone deacetylase complex, which includes Sap30, conferred a clear increase in rapamycin resistance (Fig. 2A), while mutation of the other deacetylases tested had no effect (Fig. 2A and data not shown). In support of these results, we note that deletion of the gene encoding Sap30 or the Sin3-associated protein Sbt3 has recently been shown to confer rapamycin resistance in a large-scale screening of the yeast deletion consortium strain series (7).
|
The functional significance of Rpd3 occupancy at RP gene promoters was tested by Northern blotting and chromatin immunoprecipitation. Mutations in the RPD3, SIN3, or SAP30 genes resulted in a defect in rapamycin-induced repression of RP genes (Fig. 3A). While this effect is modest (three- to fivefold as measured by phosphorimaging), it is highly reproducible in a set of mutants constructed in two different strain backgrounds (
1278b and S288C). Importantly, deletion of the RPD3 or SAP30 genes also largely prevents the loss of acetylated histone H4 from RP gene promoters that accompanies rapamycin treatment in wild-type cells (Fig. 3B). Taken together, our data indicate that the Rpd3-Sin3 histone deacetylase complex contributes to RP gene repression in the absence of Tor signaling.
|
| DISCUSSION |
|---|
|
|
|---|
Under optimal growth conditions, the Tor kinases mediate inactivation of genes subject to nitrogen catabolite repression, the retrograde response-induced genes, and stress-induced genes by regulating the phosphorylation status and thereby preventing the nuclear import of the corresponding transcription factors (2, 4, 6, 19). Here we show that, in response to nutrients, Tor signaling activates the expression of RP genes by promoting maintenance of the Esa1 histone acetyltransferase complex to RP gene promoters. Accordingly, our results demonstrate that the association of Esa1 with the RP gene promoters is rapamycin sensitive and that the loss of Esa1 from these promoters mimics the kinetics of RP gene repression upon addition of rapamycin. A formal possibility is that a decrease in RP gene expression contributes to the observed loss of Esa1 from chromatin. However, because there is no precedent for this model we do not favor this interpretation.
We find that Rap1 and Abf1 remain bound to the RP gene promoters even after inactivation of the Tor kinases with rapamycin. Analogous observations were reported when RP gene expression was repressed following amino acid starvation or heat shock (37). Moreover, recruitment of Esa1 to RP gene promoters was mapped to the Rap1 binding sites, leading to the proposal that Esa1 is recruited by Rap1 (37). Our results indicate that maintenance of Esa1 at RP gene promoters is regulated by Tor signaling. It remains to be established if the targets of this regulation are Rap1 and Abf1 and/or components of the Esa1 histone acetylase complex.
Supporting the idea that histone acetylation is linked to Tor signaling, we find that deletion of the genes encoding subunits of the Rpd3-Sin3 complex results in a defect in rapamycin-induced repression of RP genes. Furthermore, these strains also display a defect in the repression of RP genes in response to nutrient limitation. Importantly, the Rpd3-Sin3 complex preferentially deacetylates histone H4, which is the major substrate of Esa1 (1, 39, 40). Although the Rpd3-Sin3 complex is required for rDNA silencing, it has not been previously implicated in the repression of RP genes (45). Our results demonstrate that Rpd3 is present at both active and inactive RP gene promoters. Additionally, Rpd3 is present at the promoter regions as well as the coding regions of RP genes and the localization of Rpd3 to these genes does not require binding sites for Rap1 or Abf1. These results are consistent with recent reports demonstrating that untargeted and global deacetylase activity at promoters and coding regions is important for rapidly reversing the effects of localized transcription responses (17, 22).
Our results are consistent with the following model. In response to ample nutrients, Tor signaling favors the occupancy of the Esa1-histone acetylase complex at RP gene promoters resulting in histone H4 acetylation and alterations in chromatin conformation that activate transcription. In response to nutrient limitation or rapamycin treatment, Tor signaling is inhibited, leading to the release of the Esa1-histone acetylase complex from RP gene promoters. The chromatin is returned to the repressed state by the Rpd3-Sin3 histone deacetylase complex that is already resident at RP gene promoters. Our ongoing studies are focused towards understanding the signaling events between the Tor kinases and the transcription machinery at the RP gene promoters.
We suggest that histone acetylation is an important mechanism for adaptation to growth in nutrient-limiting conditions. Recent years have seen a flurry of reports establishing a connection between the Sir2 histone deacetylase complex and aging (12, 24). Sir2 is thought to regulate life span by blocking inappropriate gene expression. Most interesting is that the NAD-dependent activity of Sir2 may provide a link between chromatin acetylation and the overall metabolism of a cell. We therefore find it intriguing that, in mammalian cells, rapamycin treatment results in a gene expression profile that resembles one seen with amino acid limitation (32).
Rapamycin is having a dramatic impact on clinical medicine in several arenas. Approved for use in cases of transplant rejection in 1999, rapamycin is now being developed to prevent restenosis following cardiac stent surgery and most recently as a novel chemotherapy agent (16, 26, 43). The promise of rapamycin as a cancer drug is being explored in phase II and III clinical trials and recent reports have demonstrated its remarkable antitumor activity in cells where the phosphatidylinositol 3-kinase-AKT pathway is upregulated (16, 29, 34). A more complete understanding of mTor signaling should enhance the clinical utility of rapamycin. Our studies elucidating novel roles for Tor in controlling transcription in response to nutrients may provide insights into mTor signaling in human cells.
| ADDENDUM |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
This work was supported by K22 award CA94925-01 from the NCI (to M.E.C.).
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Beck, T., and M. N. Hall. 1999. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature 402:689-692.[CrossRef][Medline]
3. Berset, C., H. Trachsel, and M. Altmann. 1998. The TOR (target of rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 95:4264-4269.
4. Bertram, P. G., J. H. Choi, J. Carvalho, W. Ai, C. Zeng, T. F. Chan, and X. F. Zheng. 2000. Tripartite regulation of Gln3p by TOR, Ure2p and phosphatases. J. Biol. Chem. 275:35727-35733.
5. Brown, C. E., L. Howe, K. Sousa, S. C. Alley, M. J. Carrozza, S. Tan, and J. L. Workman. 2001. Recruitment of HAT complexes by direct activator interactions with the ATM-related Tra1 subunit. Science 292:2333-2337.
6. Cardenas, M. E., N. S. Cutler, M. C. Lorenz, C. J. D. Como, and J. Heitman. 1999. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 13:3271-3279.
7. Chan, T. F., J. Carvalho, L. Riles, and X. F. Zheng. 2000. A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). Proc. Natl. Acad. Sci. USA 97:13227-13232.
8. Clarke, A. S., J. E. Lowell, S. J. Jacobson, and L. Pillus. 1999. Esa1p is an essential histone acetyltransferase required for cell cycle progression. Mol. Cell. Biol. 19:2515-2526.
9. Crespo, J. L., K. Daicho, T. Ushimaru, and M. N. Hall. 2001. The GATA transcription factors GLN3 and GAT1 link TOR to salt stress in Saccharomyces cerevisiae. J. Biol. Chem. 276:34441-34444.
10. Dennis, P. B., A. Jaeschke, M. Saitoh, B. Fowler, S. C. Kozma, and G. Thomas. 2001. Mammalian TOR: a homeostatic ATP sensor. Science 294:1102-1105.
11. Eberharter, A., and P. B. Becker. 2002. Histone acetylation: a switch between repressive and permissive chromatin. EMBO Rep. 3:224-229.[CrossRef][Medline]
12. Guarente, L. 2000. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14:1021-1026.
13. Hardwick, J. S., F. G. Kuruvilla, J. K. Tong, A. F. Shamji, and S. L. Schreiber. 1999. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA 96:14866-14870.
14. Hecht, A., and M. Grunstein. 1999. Mapping DNA interaction sites of chromosomal proteins using immunoprecipitation and polymerase chain reaction. Methods Enzymol. 304:399-414.[Medline]
15. Hecht, A., S. Strahl-Bolsinger, and M. Grunstein. 1996. Spreading of transcriptional repressor SIR3 from telomeric heterochromatin. Nature 383:92-96.[CrossRef][Medline]
16. Hidalgo, M., and E. K. Rowinsky. 2000. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19:6680-6686.[CrossRef][Medline]
17. Katan-Khaykovich, Y., and K. Struhl. 2002. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone actylation status upon removal of activators and repressors. Genes Dev. 16:743-752.
18. Klein, C., and K. Struhl. 1994. Protein kinase A mediates growth-regulated expression of yeast ribosomal protein genes by modulating RAP1 transcriptional activity. Mol. Cell. Biol. 14:1920-1928.
19. Komeili, A., K. P. Wedaman, E. K. O'Shea, and T. Powers. 2000. Mechanism of metabolic control: target of rapamycin signaling links nitrogen quality to the activity of the Rtg1 and Rtg3 transcription factors. J. Cell Biol. 151:863-878.
20. Kuras, L., and K. Struhl. 1999. Binding of TBP to promoters in vivo is stimulated by activators and requires Pol II holoenzyme. Nature 399:609-613.[CrossRef][Medline]
21. Lascaris, R. F., W. H. Mager, and R. J. Planta. 1999. DNA-binding requirements of the yeast protein Rap1p as selected in silico from ribosomal protein gene promoter sequences. Bioinformatics 15:267-277.
22. Li, J., Q. Lin, W. Wang, P. Wade, and J. Wong. 2002. Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev. 16:687-692.
23. Lieb, J. D., X. Liu, D. Botstein, and P. O. Brown. 2001. Promoter-specific binding of Rap1 revealed by genome-wide maps of protein-DNA association. Nat. Genet. 28:327-334.[CrossRef][Medline]
24. Lin, S. J., P. A. Defossez, and L. Guarente. 2000. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289:2126-2128.
25. Mahajan, P. B. 1994. Modulation of transcription of rRNA genes by rapamycin. Int. J. Immunopharmacol. 16:711-721.[CrossRef][Medline]
26. Marx, S. O., and A. R. Marks. 2001. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104:852-855.
27. Messenguy, F., F. Vierendeels, B. Scherens, and E. Dubois. 2000. In Saccharomyces cerevisiae, expression of arginine catabolic genes CAR1 and CAR2 in response to exogenous nitrogen availability is mediated by the Ume6 (CargRI)-Sin3 (CargRII)-Rpd3 (CargRIII) complex. J. Bacteriol. 182:3158-3164.
28. Moazed, D. 2001. Enzymatic activities of Sir2 and chromatin silencing. Curr. Opin. Cell Biol. 13:232-238.[CrossRef][Medline]
29. Neshat, M. S., I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J. J. Gibbons, H. Wu, and C. L. Sawyers. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98:10314-10319.
30. Neuman-Silberberg, F. S., S. Bhattacharya, and J. R. Broach. 1995. Nutrient availability and the RAS/cyclic AMP pathway both induce expression of ribosomal protein genes in Saccharomyces cerevisiae but by different mechanisms. Mol. Cell. Biol. 15:3187-3196.[Abstract]
31. Nierras, C. R., and J. R. Warner. 1999. Protein kinase C enables the regulatory circuit that connects membrane synthesis to ribosome synthesis in Saccharomyces cerevisiae. J. Biol. Chem. 274:13235-13241.
32. Peng, T., T. R. Golub, and D. M. Sabatini. 2002. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol. 22:5575-5584.
33. Planta, R. J. 1997. Regulation of ribosome synthesis in yeast. Yeast 13:1505-1518.[CrossRef][Medline]
34. Podsypanina, K., R. T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, P. Frost, V. Dreisbach, J. Blenis, Z. Gaciong, P. Fisher, C. Sawyers, L. Hedrick-Ellenson, and R. Parsons. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA 98:10320-10325.
35. Powers, T., and P. Walter. 1999. Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae. Mol. Biol. Cell 10:987-1000.
36. Raught, B., A. C. Gingras, and N. Sonenberg. 2001. The target of rapamycin (TOR) proteins. Proc. Natl. Acad. Sci. USA 98:7037-7044.
37. Reid, J. L., V. R. Iyer, P. O. Brown, and K. Struhl. 2000. Coordinate regulation of yeast ribosomal protein genes is associated with targeted recruitment of Esa1 histone acetylase. Mol. Cell 6:1297-1307.[CrossRef][Medline]
38. Rohde, J., J. Heitman, and M. E. Cardenas. 2001. The Tor kinases link nutrient sensing to cell growth. J. Biol. Chem. 276:9583-9586.
39. Rundlett, S. E., A. A. Carmen, R. Kobayashi, S. Bavykin, B. M. Turner, and M. Grunstein. 1996. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc. Natl. Acad. Sci. USA 93:14503-14508.
40. Rundlett, S. E., A. A. Carmen, N. Suka, B. M. Turner, and M. Grunstein. 1998. Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature 392:831-835.[CrossRef][Medline]
41. Schmelzle, T., and M. N. Hall. 2000. TOR, a central controller of cell growth. Cell 103:253-262.[CrossRef][Medline]
42. Schmidt, A., T. Beck, A. Koller, J. Kunz, and M. N. Hall. 1998. The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the tryptophan permease. EMBO J. 17:6924-6931.[CrossRef][Medline]
43. Shapiro, A. M., J. R. Lakey, E. A. Ryan, G. S. Korbutt, E. Toth, G. L. Warnock, N. M. Kneteman, and R. V. Rajotte. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343:230-238.
44. Smith, E. R., A. Eisen, W. Gu, M. Sattah, A. Pannuti, J. Zhou, R. G. Cook, J. C. Lucchesi, and C. D. Allis. 1998. ESA1 is a histone acetyltransferase that is essential for growth in yeast. Proc. Natl. Acad. Sci. USA 95:3561-3565.
45. Smith, J. S., E. Caputo, and J. D. Boeke. 1999. A genetic screen for ribosomal DNA silencing defects identifies multiple DNA replication and chromatin-modulating factors. Mol. Cell. Biol. 19:3184-3197.
46. Struhl, K. 1999. Fundamentally different logic of gene regulation in eukaryotes and prokaryotes. Cell 98:1-4.[CrossRef][Medline]
47. Sussel, L., and D. Shore. 1991. Separation of transcriptional activation and silencing functions of the RAP1-encoded repressor/activator protein 1: isolation of viable mutants affecting both silencing and telomere length. Proc. Natl. Acad. Sci. USA 88:7749-7753.
48. Warner, J. R. 1999. The economics of ribosome biosynthesis in yeast. Trends Biochem. Sci. 24:437-440.[CrossRef][Medline]
49. Zaragoza, D., A. Ghavidel, J. Heitman, and M. C. Schultz. 1998. Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway. Mol. Cell. Biol. 18:4463-4470.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|